Compare · GLP-1 agonist
Orforglipron vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Orforglipron | Semaglutide | |
|---|---|---|
| Evidence | 9/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Orforglipron
Orforglipron (brand name Foundayo) belongs to the same drug family as semaglutide and tirzepatide — a group called GLP-1 receptor agonists (drugs that copy a natural gut hormone to curb appetite and steady blood sugar). But it has one big difference: it is a small molecule rather than a peptide (a…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.